Cargando…

Biweekly Hizentra® in Primary Immunodeficiency: a Multicenter, Observational Cohort Study (IBIS)

Immunoglobulin G (IgG) replacement therapy is a standard treatment for patients with primary immunodeficiency diseases (PIDs). Hizentra®, a 20% human subcutaneous IgG (SCIG), is approved for biweekly administration for PIDs. The aim of the multicenter IBIS study was to prospectively investigate the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vultaggio, Alessandra, Azzari, Chiara, Ricci, Silvia, Martire, Baldassarre, Palladino, Valentina, Gallo, Vera, Pecoraro, Antonio, Pignata, Claudio, Spadaro, Giuseppe, Graziani, Simona, Moschese, Viviana, Trizzino, Antonino, Boggia, Giorgio Maria, Matucci, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061090/ https://www.ncbi.nlm.nih.gov/pubmed/29951948 http://dx.doi.org/10.1007/s10875-018-0528-5

Ejemplares similares

Pediatric subset of primary immunodeficiency patients treated with SCIG: post hoc analysis of SHIFT and IBIS pooled data
por: Moschese, Viviana, et al.
Publicado: (2020)

Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency in Routine Clinical Practice: The VISPO Prospective Multicenter Study
por: Vultaggio, Alessandra, et al.
Publicado: (2015)

Correlations Among Subcutaneous Immunoglobulin Dosage, Immunoglobulin G Serum Pre-infusional Levels and Body Mass Index in Primary Antibody Deficiency Patients: A Pooled Analysis from the SHIFT/IBIS Studies
por: Pecoraro, Antonio, et al.
Publicado: (2020)

Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies
por: Canessa, Clementina, et al.
Publicado: (2016)

Safety and Efficacy of Hizentra® Following Pediatric Hematopoietic Cell Transplant for Treatment of Primary Immunodeficiencies
por: Patel, Niraj C., et al.
Publicado: (2023)

Treatment with Hizentra in patients with primary and secondary immunodeficiencies: a real-life, non-interventional trial
por: Viallard, J. F., et al.
Publicado: (2016)

The Italian Registry for Primary Immunodeficiencies (Italian Primary Immunodeficiency Network; IPINet): Twenty Years of Experience (1999–2019)
por: Lougaris, Vassilios, et al.
Publicado: (2020)

Efficacy and Safety of Hizentra(®), a New 20% Immunoglobulin Preparation for Subcutaneous Administration, in Pediatric Patients with Primary Immunodeficiency
por: Borte, Michael, et al.
Publicado: (2011)

Treatment Satisfaction with Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency: a Pooled Analysis of Six Hizentra® Studies
por: Mallick, Rajiv, et al.
Publicado: (2018)

Case Report: A child with NFKB1 haploinsufficiency explaining the linkage between immunodeficiency and short stature
por: Ricci, S., et al.
Publicado: (2023)

Ibis
por: Vargas Vila, José María, 1860-1933
Publicado: (1908)

Long-Term Efficacy and Safety of Hizentra® in Patients with Primary Immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials
por: Jolles, Stephen, et al.
Publicado: (2018)

Pharmacokinetic Analysis of Weekly Versus Biweekly IgPro20 Dosing in Patients With Primary Immunodeficiency
por: Rojavin, Mikhail A., et al.
Publicado: (2019)

Novel artful applications of vaccines at the horizon
por: Montin, Davide, et al.
Publicado: (2022)

Subcutaneous Immunoglobulin Replacement Therapy with Hizentra® is Safe and Effective in Children Less Than 5 Years of Age
por: Patel, Niraj C., et al.
Publicado: (2015)

Serum Free Light Chains in Common Variable Immunodeficiency Disorders: Role in Differential Diagnosis and Association With Clinical Phenotype
por: Scarpa, Riccardo, et al.
Publicado: (2020)

Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer
por: Chon, Hong Jae, et al.
Publicado: (2011)

Evaluation of safety and efficacy of a 20% Subcutaneous Immunoglobulin (Hizentra™), after a dose equivalent switch from intravenous or subcutaneous replacement therapy in a cohort of primary immunodeficient patients
por: Martin, Adriana, et al.
Publicado: (2012)

Clinical, Immunological, and Molecular Features of Typical and Atypical Severe Combined Immunodeficiency: Report of the Italian Primary Immunodeficiency Network
por: Cirillo, Emilia, et al.
Publicado: (2019)

The spreading of the invasive sacred ibis in Italy
por: Cucco, Marco, et al.
Publicado: (2021)

Targeted NGS Platforms for Genetic Screening and Gene Discovery in Primary Immunodeficiencies
por: Cifaldi, Cristina, et al.
Publicado: (2019)

Heterogeneity of Liver Disease in Common Variable Immunodeficiency Disorders
por: Pecoraro, Antonio, et al.
Publicado: (2020)

Corrigendum: Targeted NGS Platforms for Genetic Screening and Gene Discovery in Primary Immunodeficiencies
por: Cifaldi, Cristina, et al.
Publicado: (2019)

The Sacred Ibis debate: The first test of evolution
por: Curtis, Caitlin, et al.
Publicado: (2018)

The Genomic Footprints of the Fall and Recovery of the Crested Ibis
por: Feng, Shaohong, et al.
Publicado: (2019)

Posterior scleritis after biweekly aflibercept intravitreal injections
por: Hébert, Mélanie, et al.
Publicado: (2022)

Correction: The Sacred Ibis debate: The first test of evolution
Publicado: (2018)

Ibis T5000: a universal biosensor approach for microbiology
por: Ecker, David J., et al.
Publicado: (2008)

IBI: Identification of Biomarker Genes in Individual Tumor Samples
por: Li, Jie, et al.
Publicado: (2019)

Safety of biweekly α(1)-antitrypsin treatment in the RAPID programme
por: Greulich, Timm, et al.
Publicado: (2018)

The Impact of SARS-CoV-2 Infection in Patients with Inborn Errors of Immunity: the Experience of the Italian Primary Immunodeficiencies Network (IPINet)
por: Giardino, Giuliana, et al.
Publicado: (2022)

High Serum β-Lactams Specific/Total IgE Ratio Is Associated with Immediate Reactions to β-Lactams Antibiotics
por: Vultaggio, Alessandra, et al.
Publicado: (2015)

Case Report: Zellweger Syndrome and Humoral Immunodeficiency: The Relevance of Newborn Screening for Primary Immunodeficiency
por: Fazi, C., et al.
Publicado: (2022)

The Evolutionary Scenario of Pediatric Unclassified Primary Antibody Deficiency to Adulthood
por: Sgrulletti, Mayla, et al.
Publicado: (2023)

Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre‐randomization phase of the Polyneuropathy And Treatment with Hizentra study
por: Mielke, Orell, et al.
Publicado: (2019)

A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States
por: Mallick, Rajiv, et al.
Publicado: (2023)

Quality of life with biweekly docetaxel and capecitabine in advanced gastro-oesophageal cancer
por: Korkeila, E. A., et al.
Publicado: (2017)

Integrated Box Interrogation System (IBIS) Preliminary Design Study
por: Croft, S, et al.
Publicado: (2003)

Pleural diseases and COVID-19: ubi fumus, ibi ignis
por: Porcel, José M.
Publicado: (2020)

Mechanisms of Action of Ig Preparations: Immunomodulatory and Anti-Inflammatory Effects
por: Matucci, Andrea, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ub7on38q08rapbpvcal8uqvo7e